论文部分内容阅读
目的:探讨威麦宁胶囊联合化疗治疗中晚期非小细胞肺癌的临床疗效。方法:将63例患者随机分为治疗组和对照组。治疗组32例,采用威麦宁胶囊3.2g/次,每日3次,口服;同时给予常规化学疗法,GP方案:吉西他滨1 000mg/m2,第1~8天静滴30min;顺铂100mg/m2,第1~3天静滴,并给予水化及利尿治疗。对照组31例,仅采用上述常规化学疗法进行治疗。两组均治疗4个月。结果:治疗组有效率(65.7%)明显高于对照组(38.7%),差异具有统计学意义(P<0.05)。结论:威麦宁胶囊联合化疗治疗中晚期非小细胞肺癌的临床疗效显著,值得临床推广应用。
Objective: To investigate the clinical effect of Weimaining capsule combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: 63 patients were randomly divided into treatment group and control group. In the treatment group, 32 cases were treated with Weimaining capsules 3.2g once daily orally, while routine chemotherapy was given. GP regimen: gemcitabine 1 000mg / m2, intravenous infusion 30 minutes on the 1st to 8th day; cisplatin 100mg / m2, 1 to 3 days intravenous infusion, and given hydration and diuretic treatment. The control group of 31 cases, only the use of the above conventional chemotherapy for treatment. Both groups were treated for 4 months. Results: The effective rate of the treatment group (65.7%) was significantly higher than that of the control group (38.7%), the difference was statistically significant (P <0.05). Conclusion: Weimaining capsules combined with chemotherapy in the treatment of advanced non-small cell lung cancer has a significant clinical effect, it is worthy of clinical application.